Overview

A Phase II Study Assessing the Efficacy of Etoposide Free Chemotherapy Plus Durvalumab (MEDI4736) in First Line Extensive Disease Small Cell Lung Cancer (SCLC)

Status:
Not yet recruiting

Trial end date:
2027-12-01

Target enrollment:

Participant gender:

Summary

The current study is intended to be a "proof of concept" to evaluate the potential value of synergy between paclitaxel carboplatin and immunotherapy. If a signal clearly shows superiority over the CASPIAN data , we will have arguments to think that the combination of paclitaxel and carboplatin is more suitable for synergy with immunotherapy than the standard etoposide and carboplatin.

Phase:

Phase 2

Details

Lead Sponsor:

Intergroupe Francophone de Cancerologie Thoracique

Treatments:

Carboplatin
Durvalumab
Paclitaxel